Sub	stitute for form 1449/P7	10		Complete if Known		
000				Application Number	10/528,928-Conf. #4646	
	SUPPI	LEME	NTAL	Filing Date	March 23, 2005	
IN	IFORMATION	ON DI	SCLOSURE	First Named Inventor	Marc H. Mercken	
S	TATEMENT	ΓBY A	APPLICANT	Art Unit	1649	
_				Examiner Name	C. Y. Wang	
Sheet	1	of	2	Attorney Docket Number	026038.0385PTUS	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (#known)			of Patentee or of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	70
Examiner Signature					Date Considered		

Signature Considered

Consider

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2		
		G. Gouras, et al., Generation and Regulation of β-Amyloid Peptide Variants by Neurons, Journal of Neurochemistry, 71(5):1920-1925, 1998.			
		T. Iwatsubo, et al., Short Communication: Full-Length Amyloid-β(1-42(43)) and Amino- Trianially Modified and Truncated Amyloid-β42(43) Deposit in Diffuse Plaques, <u>American</u> Journal of Pathology, 149(6):1823-1830, 1996.			
		J. Jarrett, et al., The Carboxy Terminus of the β Amyloid Protein Is Critical for the Seeding of Amyloid Formation: Implications for the Pathogenesis of Alzheimer's Disease, <u>Biochemistry</u> , 32(18):4694-4697, 1993.			
		G. Köhler, et al., Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity, Nature, 256: 495-497, 1975.			
		G. Köhler, et al., Fusion Between Immunoglobulin-Secreting and Nonsecreting Myeloma Cell Lines, Eur. J. Immunol., 6:292-295, 1976.			
		R. Merrifield, Solid Phase Peptide Synthesis: I. The Synthesis of a Tetrapeptide, J.Am.Chem.Soc., 85:2149-2154, 1963.			
		S. Pype, et al., Characterization of Amyloid β Peptides From Brain Extracts of Transgenic Mice Overexpressing the London Mutant of Human Amyloid Precursor Protein, <u>Journal of</u> Neurochemistry, 84:602-609, 2003.			
		D. Selkoe, Alzheimer's Disease: Genes, Proteins, and Therapy, Physiological Reviews, 81(2):741-766, 2001.			

Date

Considered

Examiner

Signature

Substitute	for form 1449/P	TO		Complete if Known		
				Application Number	10/528,928-Conf. #4646	
	SUPPI	LEME	NTAL	Filing Date	March 23, 2005	
INFO	DRMATIC	ON DI	SCLOSURE	First Named Inventor	Marc H. Mercken	
STA	TEMEN	TBY	APPLICANT	Art Unit	1649	
•				Examiner Name	C. Y. Wang	
heet	2	of	2	Attorney Docket Number	026038.0385PTUS	

	M. Vandermeeren, et al., The Functional y-Secretase Inhibitor Prevents Production of Amyloid β 1-34 in Human and Murine Cell Lines, Neuroscience Letters, 315:145-148, 2001.	
	R. Wang, et. al., The Profile of Soluble Amyloid β Protein in Cultured Cell Media: Detection and Quantification of Amyloid β Protein and Variants by Immunoprecipitation-Mass	Г
1	Spectrometry, The Journal of Biological Chemistry, 271(50):31894-31902, 1996.	

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). Papplicant is to place a check mark here if English language Translation is attached.